Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drugs and trials: lessons from Plato.

× No keyword cloud information.

13 in total

Review 1. The number, quality, and coverage of randomized controlled trials in nephrology.

Authors: Giovanni F M Strippoli; Jonathan C Craig; Francesco P Schena
Journal: J Am Soc Nephrol Date: 2004-02 Impact factor: 10.121

2. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

Authors: Janet Woodcock; Joshua M Sharfstein; Margaret Hamburg
Journal: N Engl J Med Date: 2010-09-23 Impact factor: 91.245

3. Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.

Authors: Paolo Gelosa; Cristina Banfi; Anita Gianella; Maura Brioschi; Alice Pignieri; Elena Nobili; Laura Castiglioni; Mauro Cimino; Elena Tremoli; Luigi Sironi
Journal: J Pharmacol Exp Ther Date: 2010-07-29 Impact factor: 4.030

4. Punishing health care fraud--is the GSK settlement sufficient?

Authors: Kevin Outterson
Journal: N Engl J Med Date: 2012-09-12 Impact factor: 91.245

Review 5. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors: Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal: JAMA Date: 2006-05-17 Impact factor: 56.272

6. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

Drugs and trials: lessons from Plato.

Review 1. The number, quality, and coverage of randomized controlled trials in nephrology.

2. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

3. Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.

4. Punishing health care fraud--is the GSK settlement sufficient?

Review 5. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

6. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

7. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

8. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

9. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

10. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.